Woman’s Hospital first in U.S. to join international study improving PPH

Woman’s Hospital in Baton Rouge, La. is widening its maternal health innovation through a new partnership that is bringing the Oli wearable sensor device into clinical use as part of an international research study. In March 2026, Woman’s Hospital became the first site in the U.S. to launch the global study evaluating Oli, a noninvasive device designed to identify early warning signs of postpartum hemorrhage (PPH) during labor. PPH is the leading cause of preventable maternal mortality nationwide, yet current risk assessments are largely based on patient history rather than real-time data. “Woman’s is dedicated to our mission of improving the lives of women and infants, and this study aligns with the work we do every day,” said Robert Moore, M.D., chief medical officer at Woman’s Hospital.

The Oli device is placed on a mother’s abdomen during labor and continuously collects maternal and fetal data to give clinicians real-time insight into hemorrhage risk before symptoms occur. After encouraging pilot results, the international study aims to enroll 1,000 participants across multiple sites, with Woman’s Hospital already enrolling more than 130 patients. Oli technology leaders say U.S. participation marks a critical milestone in validating the device’s effectiveness. “Launching recruitment in the U.S. reflects years of dedicated effort from our engineering, clinical, regulatory and research partners across the globe,” said Tara Croft, CEO of Baymatob, an AI-guided maternal and fetal diagnostics company and the maker of Oli.